Two years ago, Actavis PLC was a relatively small seller of generic medicines with an unpronounceable name. After it seals its $66 billion deal for Allergan Inc., announced Monday, the company would be one of the globe’s largest drug makers by sales, led by the antiwrinkle treatment Botox.. The rapid rise of Actavis was fueled by seismic changes reshaping health care, and then turbocharged by Allergan’s heated efforts to slip from the grasp of a hostile suitor. To thwart detection as they sealed the deal, executives said the...
  